Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Institut National de la Santé Et de la Recherche Médicale, France | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
The study investigates the effect of plasma myeloperoxidase (MPO) concentrations on HDL dysfunction during the acute stage of ischemic and haemorrhagic strokes.
MRI or CT scan are used to confirm the diagnosis of haemorrhagic, ischemic and mimick stroke.
Plasma anf HDL-MPO concentrations, as well as potent HDL dysfunction, are compared in the 3 cases.
The investigators hypothesis is that MPO concentrations and subsequent HDL dysfunction could be higher in ischemic strokes than in haemorrhagic ones. MPO could be a examined as a potent marker of early stage of ischemic stroke.
Plasma MPO levels could also be discriminant regarding the mimick strokes in patient exhibiting stroke clinical picture.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ischemic stroke | Patients with ischemic stroke diagnosed by MRI or CT scan |
| |
| Haemorrhagic stroke | Patients without haemorrhagic stroke diagnosed by MRI or CT scan |
| |
| Mimick stroke | Patients without haemorrhagic or ischemic stroke diagnosed by MRI or CT scan |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ischemic stroke | Other | Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan |
|
| Measure | Description | Time Frame |
|---|---|---|
| Plasma MPO concentrations | Assessment of plasma MPO concentrations during acute stage of stroke | Through study completion, an average of 6 hours |
| Measure | Description | Time Frame |
|---|---|---|
| HDL-MPO concentrations | Assessment of HDL-MPO concentrations during acute stage of stroke | Through study completion, an average of 6 hours |
| Measure | Description | Time Frame |
|---|---|---|
| HDL dysfunction | Assessment of HDL function using inhibition test on cell culture | Through study completion, an average of 6 hours |
Inclusion Criteria:
Patients with less than 12 hours stroke clinical signs:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patients with clinical picture of early stage of stroke with the first signed lasting for less than 12 hours
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Christine JUHEL, PHD | Contact | +262262359949 | christine.juhel@chu-reunion.fr | |
| David COURET, MD | Contact | +262262359000 | david.couret@chu-reunion.fr |
| Name | Affiliation | Role |
|---|---|---|
| David COURET, MD | Centre Hpospitalier Universitaire de La REUNION | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chu Reunion Island | Recruiting | Saint-Pierre | Reunion Island | 97410 | Reunion |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020521 | Stroke |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Haemorrhagic stroke | Other | Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan |
|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |